COVID-19 vaccine "ripening" mRNA technology! Modern mRNA based HIV vaccine opens human trials

• by EVOMT
• 2021-08-26

AIDS is a very harmful infectious disease. According to the statistics of the United Nations, there will be 37.7 million people infected with HIV in the world in 2020. However, up to now, there is still no way to cure AIDS in modern medicine. Once infected, it will carry the disease for a lifetime

Recently, according to the latest data released by the National Institutes of Health (NIH) clinical trial research registration, Moderna launched the human clinical trial of AIDS vaccine based on mRNA technology on August 19, local time, and plans to complete it in the spring of 2023

For many years, researchers have been studying the potential of mRNA vaccine. In this COVID-19, the mRNA based vaccine launched by Pfizer and Moderna has been proved to be widely safe and effective in preventing and reducing the severity of COVID-19 infection. Therefore, people are beginning to expect that mRNA platforms can also prevent other pathogens

It is understood that the cooperative institutions for the human test of AIDS vaccine developed by Moderna are the University of Texas at San Antonio, George Washington University, Fred Hutchinson Cancer Research Center and Emory University. The research platform is the same messenger RNA platform as the 2019 coronavirus disease vaccine of the company to further evaluate the safety and immunogenicity of HIV vaccine

A total of 56 HIV negative participants aged between 18 and 56 years were included in the trial, and two candidate vaccines, mRNA-1644 and mRNA-1644v2 Core, have passed the preliminary safety test. It is worth mentioning that this is the first human trial of an HIV vaccine based on mRNA technology

If the vaccine passes Phase 1 clinical trials, Moderna will conduct Phase 2 and Phase 3 trials to determine the effectiveness of the vaccine in preventing HIV infection in a wider population. In the future, it is expected that with the maturity of mRNA vaccine technology, the rapid launch of HIV vaccines will be accelerated